{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Number of subjects exhibiting stringent complete response, complete response, very good partial response, partial response or minor response following treatment with AUTO2","groups":[{"description":"Relapsed or refractory myeloma patients.","id":"OG000","title":"AUTO2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who received at least 1 dose (complete or partial) of AUTO2 therapy in Phase I of the study were included in this analysis. 2 patients were retreated; their best overall response is presented for this endpoint","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"Participants"}